SG11202107698XA - The atr kinase inhibitor bay1895344 for use in the treatment of a hyper-proliferative disease - Google Patents
The atr kinase inhibitor bay1895344 for use in the treatment of a hyper-proliferative diseaseInfo
- Publication number
- SG11202107698XA SG11202107698XA SG11202107698XA SG11202107698XA SG11202107698XA SG 11202107698X A SG11202107698X A SG 11202107698XA SG 11202107698X A SG11202107698X A SG 11202107698XA SG 11202107698X A SG11202107698X A SG 11202107698XA SG 11202107698X A SG11202107698X A SG 11202107698XA
- Authority
- SG
- Singapore
- Prior art keywords
- bay1895344
- hyper
- treatment
- kinase inhibitor
- proliferative disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19156399 | 2019-02-11 | ||
| PCT/EP2020/052971 WO2020165015A1 (en) | 2019-02-11 | 2020-02-06 | The atr kinase inhibitor bay1895344 for use in the treatment of a hyper-proliferative disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202107698XA true SG11202107698XA (en) | 2021-08-30 |
Family
ID=65408941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202107698XA SG11202107698XA (en) | 2019-02-11 | 2020-02-06 | The atr kinase inhibitor bay1895344 for use in the treatment of a hyper-proliferative disease |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220117973A1 (en) |
| EP (1) | EP3923951A1 (en) |
| JP (1) | JP7677897B2 (en) |
| KR (1) | KR20210126589A (en) |
| CN (1) | CN113412114A (en) |
| AU (1) | AU2020221473A1 (en) |
| BR (1) | BR112021013869A2 (en) |
| CA (1) | CA3129346A1 (en) |
| CL (1) | CL2021002098A1 (en) |
| EA (1) | EA202192180A1 (en) |
| IL (1) | IL285136A (en) |
| JO (1) | JOP20210215A1 (en) |
| MA (1) | MA54928A (en) |
| MX (1) | MX2021009550A (en) |
| SG (1) | SG11202107698XA (en) |
| TW (1) | TWI848047B (en) |
| WO (1) | WO2020165015A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI656121B (en) | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | 2-(morpholin-4-yl)-1,7-naphthyridine |
| EP3661560B1 (en) | 2017-08-04 | 2025-02-26 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors |
| CN116925070A (en) * | 2022-04-24 | 2023-10-24 | 扬子江药业集团有限公司 | Substituted aza-fused ring compounds and medical uses thereof |
| WO2024188937A1 (en) | 2023-03-13 | 2024-09-19 | Bayer Aktiengesellschaft | Combinations of atr kinase inhibitors and parp inhibitors to treat hyper-proliferative conditions e.g. cancer |
| KR20250007405A (en) | 2023-07-05 | 2025-01-14 | 액티부키 주식회사 | Electronic device for realizing digital twin techonology and its operating method |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI656121B (en) * | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | 2-(morpholin-4-yl)-1,7-naphthyridine |
| EP3402795B1 (en) * | 2016-01-14 | 2019-10-30 | Bayer Pharma Aktiengesellschaft | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines |
| WO2018153970A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Solid forms of 2-[(3r)-3-methylmorpholin-4-yl]-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine |
| UY37616A (en) * | 2017-02-24 | 2018-09-28 | Bayer Ag | COMBINATION OF QUINASA ATR INHIBITORS WITH RADIO SALT-223 |
| CA3054247A1 (en) * | 2017-02-24 | 2018-08-30 | Antje Margret Wengner | Combination of atr kinase inhibitors with parp inhibitors |
| CA3054248A1 (en) * | 2017-02-24 | 2018-08-30 | Bayer As | Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor |
| JOP20190197A1 (en) * | 2017-02-24 | 2019-08-22 | Bayer Pharma AG | An inhibitor of atr kinase for use in a method of treating a hyper-proliferative disease |
| US11712440B2 (en) * | 2017-12-08 | 2023-08-01 | Bayer Aktiengesellschaft | Predictive markers for ATR kinase inhibitors |
-
2020
- 2020-02-06 MA MA054928A patent/MA54928A/en unknown
- 2020-02-06 SG SG11202107698XA patent/SG11202107698XA/en unknown
- 2020-02-06 CA CA3129346A patent/CA3129346A1/en active Pending
- 2020-02-06 EA EA202192180A patent/EA202192180A1/en unknown
- 2020-02-06 MX MX2021009550A patent/MX2021009550A/en unknown
- 2020-02-06 WO PCT/EP2020/052971 patent/WO2020165015A1/en active Application Filing
- 2020-02-06 JO JOP/2021/0215A patent/JOP20210215A1/en unknown
- 2020-02-06 BR BR112021013869-2A patent/BR112021013869A2/en unknown
- 2020-02-06 AU AU2020221473A patent/AU2020221473A1/en active Pending
- 2020-02-06 JP JP2021546746A patent/JP7677897B2/en active Active
- 2020-02-06 KR KR1020217025277A patent/KR20210126589A/en active Pending
- 2020-02-06 TW TW109103777A patent/TWI848047B/en active
- 2020-02-06 CN CN202080013492.1A patent/CN113412114A/en active Pending
- 2020-02-06 US US17/310,483 patent/US20220117973A1/en not_active Abandoned
- 2020-02-06 EP EP20702491.0A patent/EP3923951A1/en active Pending
-
2021
- 2021-07-26 IL IL285136A patent/IL285136A/en unknown
- 2021-08-10 CL CL2021002098A patent/CL2021002098A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022521683A (en) | 2022-04-12 |
| IL285136A (en) | 2021-09-30 |
| EA202192180A1 (en) | 2022-01-13 |
| KR20210126589A (en) | 2021-10-20 |
| MX2021009550A (en) | 2021-09-08 |
| BR112021013869A2 (en) | 2021-09-21 |
| CN113412114A (en) | 2021-09-17 |
| US20220117973A1 (en) | 2022-04-21 |
| AU2020221473A1 (en) | 2021-08-05 |
| TWI848047B (en) | 2024-07-11 |
| MA54928A (en) | 2021-12-22 |
| EP3923951A1 (en) | 2021-12-22 |
| TW202045185A (en) | 2020-12-16 |
| CL2021002098A1 (en) | 2022-02-25 |
| CA3129346A1 (en) | 2020-08-20 |
| WO2020165015A1 (en) | 2020-08-20 |
| JOP20210215A1 (en) | 2023-01-30 |
| JP7677897B2 (en) | 2025-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285136A (en) | The atr kinase inhibitor bay1895344 for use in the treatment of a hyper-proliferative disease | |
| IL268307A (en) | An inhibitor of atr kinase for use in a method of treating a hyper-proliferative disease | |
| IL288231A (en) | An inhibitor of jak1/2 or a pharmaceutically acceptable salt thereof and an inhibitor of pi3k or a pharmaceutically acceptable salt thereof, for use in the treatment of myelofibrosis | |
| IL274716A (en) | Synthesis of a bruton's tyrosine kinase inhibitor | |
| IL292530B2 (en) | Pyruvate kinase activators for use in treating blood disorders | |
| IL279260A (en) | Kdm1a inhibitors for the treatment of disease | |
| IL249596B (en) | Compound that inhibits atr protein kinase and a compound that inhibits chk1 protein kinase for use in treating cancer | |
| ZA201805439B (en) | Bruton's tyrosine kinase inhibitors | |
| IL276489A (en) | Atr inhibitor and application thereof | |
| IL254142B (en) | Tradipitant for use in the treatment of a tradipitant-responsive disease or condition | |
| IL282270A (en) | An aurora a kinase inhibitor for use in the treatment of neuroblastoma | |
| ZA201906887B (en) | Bruton's tyrosine kinase inhibitors | |
| IL251816B (en) | A pharmaceutical combination comprising alvocidib and bromodomain (brd) inhibitor for use in the treatment of cancer | |
| PL3302519T3 (en) | Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease | |
| IL284856A (en) | A dbait molecule in combination with kinase inhibitor for the treatment of cancer | |
| HUE065374T2 (en) | RET inhibitor for use in the treatment of cancer containing a RET mutation | |
| IL283687A (en) | Usp19 inhibitors for use in therapy | |
| GB201702160D0 (en) | Inhibitors for use in therapy | |
| ZA202202617B (en) | Treatment of cancer using a combination comprising multi-tyrosine kinase inhibitor and immune checkpoint inhibitor | |
| IL284307A (en) | Lta4h inhibitors for the treatment of hidradenitis suppurativa | |
| SI4072532T1 (en) | Dosage form for use in treating or preventing of a disease | |
| GB201807845D0 (en) | Kinase Inhibitors | |
| HK40075509A (en) | Dosage form for use in treating or preventing of a disease | |
| GB2593841B (en) | Low dosage hydrate inhibitor | |
| HK40050334A (en) | An aurora a kinase inhibitor for use in the treatment of neuroblastoma |